Bupropion as a modulator of drug activity
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
1. A method of treating major depressive disorder, comprising:
orally administering, to an adult human suffering from major depressive disorder, a dosage form comprising:
about 105 mg of bupropion hydrochloride, formulated for sustained release and
about 45 mg of a dextromethorphan, formulated for immediate release, as the only therapeutically active compounds in the dosage form;
wherein the dosage form is administered once a day for the first three days, and twice a day thereafter so that the 105 mg of bupropion hydrochloride and the 45 mg of the dextromethorphan are administered once a day or twice a day for at least 14 days.
2. The method of claim 1 , wherein the dextromethorphan is dextromethorphan hydrobromide.
3. The method of claim 1 , wherein the adult human has a C max of bupropion that is about 90 ng/mL after 8 days of dosing.
4. The method of claim 1 , wherein the adult human has an AUC 0-12 of bupropion that is about 600 ng·hr/mL after 8 days of dosing.
5. The method of claim 1 , wherein the adult human has an AUC 0-12 of bupropion that is about 700 ng·hr/mL after 8 days of dosing.
6. The method of claim 1 , wherein the adult human has an AUC 0-12 of bupropion that is about 600 ng·hr/mL to about 700 ng·hr/mL after 8 days of dosing.
7. The method of claim 1 , wherein the adult human is suffering from treatment-resistant major depressive disorder.
8. The method of claim 1 , wherein the dosage form further comprises microcrystalline cellulose.
9. The method of claim 1 , wherein the dosage form further comprises magnesium stearate.
10. The method of claim 1 , wherein the adult human has a T max of dextromethorphan that is about 4 hours after 8 days of dosing.
11. The method of claim 1 , wherein the administration of the dosage form yields an increased elimination half-life of dextromethorphan as compared to a corresponding elimination half-life of dextromethorphan, were the dextromethorphan administered alone.
12. The method of claim 1 , wherein administration of the dosage form results in the adult human experiencing an improvement of a depressive symptom.
13. The method of claim 12 , wherein the depressive symptom comprises sadness.
14. The method of claim 12 , wherein the depressive symptom comprises reduced sleep.
15. The method of claim 12 , wherein the depressive symptom comprises reduced appetite.
16. The method of claim 12 , wherein the depressive symptom comprises difficulty concentrating.
17. The method of claim 12 , wherein the depressive symptom comprises lassitude.
18. The method of claim 12 , wherein the depressive symptom comprises pessimism.
19. The method of claim 1 , wherein the administration of the dosage form yields higher systemic exposure to dextromethorphan as compared to a corresponding systemic exposure to dextromethorphan, were the 45 mg of the dextromethorphan administered alone.